Citation Impact
Citing Papers
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
Targeting cancer stem cell pathways for cancer therapy
2020
N6-methyladenosine Modulates Messenger RNA Translation Efficiency
2015 Standout
Post-transcriptional gene regulation by mRNA modifications
2016 Standout
Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism
2018 Standout
Dynamic RNA Modifications in Gene Expression Regulation
2017 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases
2017
Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets
2011
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Hallmarks of Cellular Senescence
2018 Standout
Reading, writing and erasing mRNA methylation
2019 Standout
Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain
2014
Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?
2009
Works of Markus Jaeger being referenced
Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications
2013
Expression of tumor-promoting Cyr61 is regulated by hTRA2- 1 and acidosis
2011
Hypoxia‐dependent mRNA expression pattern of splicing factor YT521 and its impact on oncological important target gene expression
2013
Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study
2008
Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: Results of a phase I/II study
2004
Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: Results of a phase I/II study
2004